|
1
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cappuzzo F, Jänne PA, Skokan M,
Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi
L, Toschi L, et al: MET increased gene copy number and primary
resistance to gefitinib therapy in non-small-cell lung cancer
patients. Ann Oncol. 20:298–304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takezawa K, Parazzoli V, Arcila ME, Nebhan
CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ,
Melnick MA, et al: HER2 amplification: A potential mechanism of
acquired resistance to EGFR inhibition in EGFR-mutant lung cancers
that lack the second-site EGFR T790M mutation. Cancer Discov.
2:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang L and Fu L: Mechanisms of resistance
to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5:390–401.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim J and Thiery JP:
Epithelial-mesenchymal transitions: Insights from development.
Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janjigian YY, Smit EF, Groen HJ, Horn L,
Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, et al:
Dual inhibition of EGFR with afatinib and cetuximab in kinase
inhibitor-resistant EGFR-mutant lung cancer with and without T790M
mutations. Cancer Discov. 4:1036–1045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR, TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishii H, Azuma K, Sakai K, Kawahara A,
Yamada K, Tokito T, Okamoto I, Nishio K and Hoshino T: Digital PCR
analysis of plasma cell-free DNA for non-invasive detection of drug
resistance mechanisms in EGFR mutant NSCLC: Correlation with paired
tumor samples. Oncotarget. 6:30850–30858. 2015.PubMed/NCBI
|
|
13
|
Bordi P, Del Re M, Danesi R and Tiseo M:
Circulating DNA in diagnosis and monitoring EGFR gene mutations in
advanced non-small cell lung cancer. Transl Lung Cancer Res.
4:584–597. 2015.PubMed/NCBI
|
|
14
|
Jorge SE, Kobayashi SS and Costa DB:
Epidermal growth factor receptor (EGFR) mutations in lung cancer:
Preclinical and clinical data. Braz J Med Biol Res. 47:929–939.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piotrowska Z, Niederst MJ, Karlovich CA,
Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman
EL, Kalsy A, et al: Heterogeneity underlies the emergence of
EGFRT790 wild-type clones following treatment of T790M-Positive
cancers with a third-generation EGFR inhibitor. Cancer Discov.
5:713–722. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morinaga R, Okamoto I, Furuta K, Kawano Y,
Sekijima M, Dote K, Satou T, Nishio K, Fukuoka M and Nakagawa K:
Sequential occurrence of non-small cell and small cell lung cancer
with the same EGFR mutation. Lung Cancer. 58:411–413. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Furugen M, Uechi K, Hirai J, Aoyama H,
Saio M, Yoshimi N, Kinjo T, Miyagi K, Haranaga S, Higa F, et al: An
autopsy case of two distinct, acquired drug resistance mechanisms
in epidermal growth factor receptor-mutant lung adenocarcinoma:
Small cell carcinoma transformation and epidermal growth factor
receptor T790M mutation. Intern Med. 54:2491–2496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Popat S, Wotherspoon A, Nutting CM,
Gonzalez D, Nicholson AG and O'Brien M: Transformation to ‘high
grade’ neuroendocrine carcinoma as an acquired drug resistance
mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer. 80:1–4.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fallet V, Ruppert AM, Poulot V, Lacave R,
Belmont L, Antoine M, Cadranel J, Wislez M and Lavolé A: Secondary
resistance to erlotinib: Acquired T790M mutation and small-cell
lung cancer transformation in the same patient. J Thorac Oncol.
7:1061–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Costa DB and Kobayashi SS: Whacking a
mole-cule: Clinical activity and mechanisms of resistance to third
generation EGFR inhibitors in EGFR mutated lung cancers with
EGFR-T790M. Transl Lung Cancer Res. 4:809–815. 2015.PubMed/NCBI
|
